Indeed, many of the new generation of antidepressant and antipsychotic medications possess 5HT2 antagonist properties (Anttila and Leinonen 2001; Poyurovsky et al. 2003; Tyson et al. 2004), and our results suggest that early CPF exposure could lead to a subpopulation that is vulnerable to cognitive impairment by these agents, compromising their utility. Here, HTR2A is linked to Cognitive impairment.